Point your AI agent at freehire and let it find you a job.

Get the CLI →

Vaxcyte

Developing vaccines to prevent and treat bacterial diseases.

H-1B sponsor history — This employer has had H-1B petitions approved by USCIS in the last five fiscal years, per the USCIS H-1B Employer Data Hub. The approval belongs to the employer and is not a commitment to sponsor this role.
Discussion
biotechhealthcarepharmaceuticals

Company facts

Founded
2013
Employees
507
Headquarters
United States
CEO
Grant Pickering
Type
Public
Listed
NASDAQ: PCVX

About

Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California, that is dedicated to creating high-fidelity vaccines to combat serious bacterial infections. We focus on critical pathogens such as Streptococcus pneumoniae, Group A Streptococcus, periodontitis, and Shigella — diseases that signify an enormous public health burden due to their prevalence and impact. Our unique approach leverages advanced chemistry and modern synthetic techniques, including our proprietary XpressCF™ cell-free protein synthesis platform, allowing us to engineer vaccines that are both powerful and scalable. The lead product candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) that has been granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults. This innovation not only aims to cover the existing serotypes responsible for pneumococcal disease in circulation but is also anticipated to provide greater immunogenicity compared to traditional PCVs, thanks to our carrier-sparing technology. Following VAX-24, we are developing even broader candidates such as VAX-31 alongside preclinical programs targeting other serious bacterial infections.

24 jobs

Tailor your CV for this role?

We couldn't check your fit for this role — add a CV to your profile to see it next time.

A new version of freehire is available